Negma

  • Financing, available in multiple tranches over the next three years, could extend the Company’s runway into Q4 2024
  • Transaction will enable Evaxion to advance its next-generation cancer vaccine, EVX-03, towards a Phase 1 clinical trial

Copenhagen, DENMARK, Aug. 01, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that it has entered into a binding agreement for a financing of up to USD 20 million with Negma Group Investment Ltd, a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach.

“We are excited to collaborate with Evaxion. At Negma Group, we invest in people who bring forth forward-thinking, data-driven solutions. We have been very impressed by both the scientific innovation and expertise of the Evaxion team, and the clinical data presented to date for the programs in oncology. We are proud to partner with Evaxion as they advance the next-generation personalized cancer vaccines to develop superior immunotherapies for patients in need,” said Sophie Villedieu, Equity Capital Market of Negma Group. “We are pleased to be able to establish a flexible financing vehicle with Negma Group. The ability to attract such an experienced investor is a tribute to Evaxion’s AI technology and pipeline progress,” said Per Norlén, Chief Executive Officer of Evaxion.

Financing is available in tranches of up to USD 700,000 over a period of 36 months. Executing individual tranches and the timing of such tranches is at the discretion of Evaxion subject to certain terms and conditions. The convertible bonds carry a zero coupon and will be issued at a subscription price corresponding to their par value. The conversion price will be determined as 83.5% of the second lowest closing volume weighted average share price (VWAP) of at least 8 trading days immediately preceding the issuance of each conversion request by Negma.

The financing commitments are intended to cover the Company’s working capital needs, including the ongoing clinical phase 2 trial of EVX-01, and the advancement of EVX-03 towards the initiation of a Phase 1 clinical trial. If Evaxion fully utilizes the convertible note program, the company will have sufficient financing to fund its planned activities into Q4 2024.

Evaxion plans to announce the interim results of the clinical Phase 2 study with EVX-01 in patients with metastatic melanoma in Q4 2023, a program where promising Phase 1/2a data were presented at ASCO in June 2023. In addition, the Company plans to initiate a Phase 1 clinical trial with EVX-03 in patients with lung cancer and other solid tumors. EVX-03 is based on the use of Evaxion´s proprietary AI-technology and novel ObsERV™ platform, which enables the Company to identify new patient-specific tumor targets called ERVs to enhance the efficacy of its personalized cancer vaccines, with potential to broaden the utility to patients unresponsive to current immunotherapies.

(Alliance News) – Fenix Entertainment Spa announced that its board of directors has examined and approved “an overall capital and financial strengthening operation,” based on the issuance of a cum warrant bond, reserved for subscription to the investor Negma Group, in the amount of EUR10.0 million, to be issued in one or more tranches.

In particular, “this decision,” the company explains in a note, “has matured taking into account the need for the company to provide itself with a suitable instrument. On one hand, to raise new capital to financially support the three-year investment plan 2023-2025 and, on the other hand, to achieve an economic, equity and financial rebalancing, as already communicated to the market on November 4, 2022.

Milan, Sept. 13, 2022 – EEMS Italia S.p.A. (“EEMS Italia” or the “Company”), an Italian company active as a wholesaler in the energy market, listed on the Euronext Milan market organized and managed by Borsa Italiana S.p.A., hereby announces that it has today signed an agreement with Negma Group Investment LTD, a professional investor based in Dubai (“Negma” or the “Investor”), a new investment agreement (the “Negma Investment Agreement”) concerning a program of financing of EEMS Italia by issuing a bond convertible into EEMS Italia ordinary shares reserved for the Investor (the “Negma Convertible Bond”).

The Negma Convertible Bond will consist of convertible bonds with a nominal amount of 10 thousand euros each (the “Bonds”), for a total maximum amount of 20 million euros and will be submitted for approval to the forthcoming Extraordinary Shareholders’ Meeting, which will be also called to express an opinion on the related divisible capital increase, with the exclusion of of option rights, to service the related conversion.

The Negma Investment Agreement has a structure, amount and terms substantially in line with the previous one already entered into with Nice & Green S.A. (“N&G”), dated November 3, 2021, whose related convertible bond will, therefore, be replaced by the Negma Convertible Bond.

Negma is a primary operator and professional in the financial sector that will replace N&G and the related convertible bond approved by the Extraordinary Shareholders’ Meeting on December 15, 2021, in view of the gradual unwillingness of N&G that has emerged since last August to continue the relationship with the Company and to follow up on the related subscription program.

On September 13, 2022, therefore, the Board of Directors of EEMS Italia took note of Negma’s greater alignment with the future development programs of the EEMS Group, also in view of the uncertainties affecting the gas business related to the persistent international situation.

Specifically, the Negma Investment Agreement provides for a program – with a duration of 24 months from the first issue, extendable to 36 months upon request of EEMS Italia – of 20 issues (each of a countervalue of a maximum of one million euros) of unlisted Bonds convertible into shares listed shares of the Company.

The Company will have the right (and not the obligation) to request Negma to subscribe for the tranches; each issue will be interest-free and with a term of 12 months; Negma may request the conversion of the Bonds at any time from their issuance, and in case of failure to request the Bonds will be converted into EEMS Italia listed shares upon their maturity, unless EEMS Italia opts for their redemption. The conversion price is equal to a percentage of the lowest daily volume-weighted average price for the volumes traded (VWAP, “Volume Weighted Average Price”) of the Company’s shares, recorded during the 12 open market days preceding the date of the conversion request. The conversion ratio is determined on the basis of the par value of each bond divided by the conversion price.

The signing of the Negma Investment Agreement and the Negma Convertible Bond will enable the Company to be able to continue to rely on the availability, with the flexibility typical of such an instrument, of resources on the market to be allocated to meet the Company’s liquidity needs necessary to implement its business plan, within the time horizon contemplated by the Negma Convertible Bond and to develop all the activities envisaged in the strategic guidelines of reference.

The Board of Directors, in the context of the approval of the Negma Investment Agreement has, accordingly, resolved to convene the Extraordinary Shareholders’ Meeting of the Company for October 24, 2022 in first call and, if necessary, for October 25, 2022 in second call, to propose the approval of the bond issue up to a maximum of 20,000,000 euros convertible into EEMS Italia S.p.A. listed shares to be issued in one or more tranches, and related share capital increase pursuant to Article 2420-bis, paragraph 2, of the Civil Code Civil Code, on a divisible basis, with the exclusion of option rights pursuant to Article 2441, paragraph 5, of the Civil Code, for a maximum amount of 20,000,000 euros, including any share premium, to service the related conversion, subject to revocation of the resolutions to issue convertible bonds and the related capital increase adopted by the Extraordinary Shareholders’ Meeting of December 15 December 2021 to the extent not used.

For more detailed information on the transaction and the characteristics of the convertible bond reserved for Negma and the related divisible capital increase, please refer to the related Explanatory Report of the Board of Directors, which will be made available available to the public at least twenty-one days before the Shareholders’ Meeting in the manner prescribed by the laws and regulations in force, together with the auditors’ opinion on the fairness of the issue price of the compendium shares to service the conversion of the Bonds.

To support the process of growth and business development, envisaged in the Business Plan 2022-2026 and be able in the near future as well, to quickly and with maximum flexibility the financial means necessary to promptly seize the opportunities that arise in the market, the Board of Directors deemed it appropriate to include in the Agenda of the Extraordinary Shareholders’ Meeting to be convened, including the granting to the Board of Directors a proxy to increase the share capital by a maximum amount of 100 million, including any share premium, to be carried out also in one or more tranches, within five years from the date of the resolution, pursuant to Articles 2420-ter and 2443 of the Civil Code, also with the exclusion of option rights pursuant to Article 2441, paragraphs 4 and 5, of the Civil Code and also by issuing convertible bonds and/or warrants. It should be noted that the timing of the exercise of the authorization, as well as the terms and conditions of any issues, will depend on the concrete opportunities that arise and will be communicated to the market in accordance with the law and regulations as soon as they are determined by the Board of Directors.

In addition, the Board of Directors, will propose to the convening Shareholders’ Meeting certain amendments bylaws (amending Articles 5, 6, 7, 9, 13, 14, 15, 16, 19, 21, 24, 25, 26, 27, 28, 31, 32, 33 and deletion of Art. 30) in order to, inter alia, update and/or supplement the bylaws in light of regulatory developments, notarial guidelines and the latest market practices.

For further information, please refer to the Board of Directors’ Report on the updating of the bylaws and the granting of powers to the administrative body pursuant to accordance with Articles 2420-ter and 2443 of the Civil Code, which will be made available to the public, together with the notice of the Extraordinary Shareholders’ Meeting, at least 30 days before the meeting, in the manner prescribed by applicable laws and regulations; the notice of the meeting will also be published in extracts in daily newspapers. Additional documentation required by the law, including regulations, in force will be published in the manner and within the terms of the law and regulations.

At today’s meeting, the Board of Directors finally approved, subject to the favorable opinion of the Management Control Committee, a financing transaction of up to 1,000,000 euros with the parent company Gruppo Industrie Riunite S.r.l., qualifying as a transaction of greater significance with a related party. The related disclosure document prepared pursuant to Article 5 of the Regulations adopted by Consob with Resolution No. 17221 of March 12, 2010, as subsequently amended and supplemented, will be made available to the public within 7 days from today’s date in the manner prescribed by the law, including regulations, in force.

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a financing commitment of up to SEK 200 million (“Transaction”) with Negma Group Ltd, a Paris-based leading financial institution (“Negma”). The Company has also entered into a binding commitment letter to receive a shareholder loan up to SEK 50 million with its existing shareholder Van Herk Investments.

The financing commitments will allow the Company to reach its next clinical read-outs from the ongoing ADVANCE II and ALISON trials, to prepare for next clinical trials and to establish pivotal-stage and commercial manufacturing for its lead program DCP-001.

Based on the commitment letter signed with Van Herk Investments, the Company is entitled to receive from Van Herk Investments a shareholder loan up to a maximum amount of SEK 50 million at market-standard conditions. The commitment letter is valid until June 30, 2023.

Negma has committed to subscribe to up to SEK 200 million in convertible bonds. Financing is available in tranches of up to SEK 10 million over a period of 30 months following closing of the Transaction. Executing individual tranches and the timing of such tranches is at the sole discretion of the Company, subject to certain terms and conditions. The convertible bonds carry a zero coupon and will be issued at a subscription price corresponding to their par value. The conversion price will be determined as 92% of the second lowest closing volume weighted average share price (VWAP) of the 10 consecutive trading days preceding the issuance of conversion request by Negma. The Company will inform the market regarding issuance and conversion of convertible bonds into shares in accordance with applicable regulations. The commitment from Negma is subject to a definitive agreement being entered into between the parties, which is estimated to take place in the forthcoming days.

Mendus plans to announce updated results and survival outcomes from the ADVANCE II clinical trial evaluating its lead cancer program DCP-001 in Acute Myeloid Leukemia (AML) maintenance therapy in Q4 2022. Positive interim results reported in May 2022 have demonstrated a successful outcome on the primary study endpoint of measurable residual disease (MRD), including first clear signals that MRD responses translate into relevant survival benefit. Mendus will also present first clinical results from the ALISON trial evaluating DCP-001 in ovarian cancer at the European Society of Gynecological Oncology (ESGO) conference, held October 27-30 and is preparing for a next clinical trial in gastro-intestinal stromal tumors with its intratumoral immune primer ilixadencel.

“We are pleased to have secured a robust and flexible financing and have been able to attract an experienced investor with Negma Group, together with additional commitment from our largest shareholder Van Herk Investments,” commented Erik Manting, PhD, Chief Executive Officer of Mendus. ”The financing will support Mendus in realizing the survival endpoints and read-outs of the ADVANCE II trial and significant additional near-term clinical value inflection points, while also allowing us to further strengthen the manufacturing capabilities supporting the long-term success of our company.”

“We are excited to collaborate with Mendus. The Company already has a strong investor basis and is pursuing clearly differentiated and innovative therapeutic strategies in areas with significant unmet medical needs in oncology. Negma is happy to provide a flexible financing solution supporting the company in reaching its next milestones,” commented jointly Anthony de Rauville, CIO and Sophie Villedieu, Associate ECM of Negma Group.

Van Lanschot Kempen N.V. (Kempen & Co) acted as financial adviser for the transaction with Negma and Delphi acted as legal adviser for the transaction with Negma and the commitment letter by Van Herk Investments.

Villeurbanne, France, July 21st, 2022 – 07:30 am CEST – NAVYA (FR0013018041- Navya), an autonomous mobility systems leader, announced the signing of a funding agreement on July 20th with the Negma Group for a total nominal amount of €36 million. Negma is an investment group that is based in Dubai in the United Arab Emirates and operates worldwide. Under the terms of the agreement the financing will take the form of convertible bonds to which a warrant for Negma to purchase shares of Navya’s capital stock is attached, each share having a nominal value of €2,500 and a maturity of twelve (12) months.

With an initial injection of €2.5 million, the funding from Negma represents an immediate improvement of Navya’s cash flow and the first step in its investment strategy, allowing it to pursue its technological roadmap, thus enabling its transition toward industrialization and speed up its entry into the markets of those regions where autonomous mobility solutions are in ever increasing demand.

With its finances on a solid footing thanks to the funding agreement, Navya will be in a position to support its development cycle in the medium term and facilitate progress on its technological and commercial projects. As a leading investment group with the aim of promoting growth and value creation, Negma will not only provide Navya with flexible financing solutions to ensure its large-scale industrialization, but will also enable it to dynamize its strategic and operational performance across its value chain.

“This funding operation is a logical step on our strategic roadmap toward growth. Our partnership with the Negma Group will enable us to speed up the development of Navya and boost our capacity in the markets where demand is high. This first investment plan means that Navya will be able to implement its technological roadmap with confidence and will be in a position to deploy locally at scale in strategic regions like the Middle East. With its innovative and flexible funding solutions, the Negma Group is a strategic investor that provides the opportunity for high potential companies like Navya to scale up their activities. Along with the Supervisory Board, we are delighted to be able to count on such support for our growth and for building sustainable autonomous mobility, both of which will contribute to our success.”

Sophie Desormière, CEO of Navya

“Negma’s involvement in this exciting business project bears witness to our willingness to support the profitable growth of a future world mobility leader, capable of rolling out new forms of technology to meet the challenges of the ecological transition and the fluidity problems of the cities and private spaces of tomorrow on a global scale.”

Elaf Gassam, Chairman of the Negma Group, and François Houssin, Managing Partner of the Negma Group

A detailed explanation of how convertible bonds with stock acquisition rights work is available on Navya’s website.

NAVYA is listed on the Euronext regulated market in Paris (ISIN code: FR0013018041- Navya). Further details: www.navya.tech

Issy-les-Moulineaux, le 12 mai 2022 18h00 – Alan Allman Associates (Euronext Paris – FR0000062465 – l’« Ecosystème » – AAA), écosystème de cabinets de conseil à l’international, annonce avoir mis en place un financement obligataire pour un montant maximum d’un million d’euros auprès de Negma group Ltd, un fond d’investissement spécialisé.

Ce financement prend la forme d’une émission d’obligations convertibles en actions, sans BSA attachés sur le fondement de la délégation de compétence consentie par l’Assemblée générale extraordinaire du 23 juin 2021, aux termes de sa 18ème résolution.

La première tranche de 250.000 euros est tirée à la signature du contrat. Le tirage et le quantum des tranches est à la main de la Société. La durée d’engagement maximum de l’Investisseur est de 24 mois à compter de ce jour.

Les obligations convertibles ne porteront pas d’intérêt et auront une maturité de 12 mois à compter de leur émission. Elles pourront être converties à tout moment par leur porteur en actions Alan Allman Associates dans une période d’un an suivant l’émission. Elles devront toutefois être remboursées en cas de survenance d’un cas de défaut usuel en pareille matière.

Cette ligne de financement permet surtout à Alan Allman Associates de bénéficier d’un outil de liquidité, pour permettre à un investisseur extérieur de placer des titres supplémentaires dans le marché.

Les obligations convertibles ne feront pas l’objet d’une demande d’admission aux négociations sur le marché Euronext Paris et ne seront par conséquent pas cotées. Cette opération ne donne pas lieu à l’établissement d’un prospectus soumis au visa de l’AMF.

A propos d’Alan Allman Associates

Alan Allman Associates est un écosystème de marques fortes, spécialisé notamment dans la transformation digitale, créé en 2009 par acquisitions et développement de performance interne, dans l’univers du conseil. Implanté en Europe et en Amérique au Nord, l’Ecosystème entretient un réseau de relations dynamiques, créatrices de valeur autour de 3 pôles : conseil high-tech, conseil en transformation industrielle et conseil en stratégie. Alan Allman Associates est labellisé Happy At Work, certifié ISO 9001 et médaillé Silver Ecovadis pour sa performance RSE.

Alan Allman Associates est coté sur le Compartiment B d’Euronext Paris (FR0000062465 – mnémonique AAA).

Negma Group, investment company, and FAI, an Italian expert in restructuring and acquisitions, announce the acquisition
of ZILLI house with the approval of the Chairman of the Commercial Court of Lyon.


Founded in 1965 by Alain Schimel, ZILLI is a French house reputed in the world of men’s fashion, particularly for its pioneering
role in the invention of the luxury leather jacket. A global reference for more than 50 years, with the Living Heritage Company
label. Refined by the craftsmen and women in its Lyon workshops, the selection of rare hides and exceptional fabrics are
transformed into unique creations. Over the years ZILLI has developed a complete luxury menswear wardrobe: from suits to
shirts, small leather goods, belts, knitwear, jeans, footwear, eyewear. Today, the ZILLI universe shines in the world’s most
beautiful cities, with its stores at the most prestigious addresses.


The aim of the Negma Group and Fai is to consolidate ZILLI house and to set it up as a key player in luxury menswear.
To highlight its identity and the history that it has built up over more than 50 years and capitalize on its Lyon-based expertise.


In real terms, the project consists of strengthening the current markets and rapidly developing the Middle East, European
and Asian markets.


Priority investments will be made in the marketing and communication departments in order to modernize its image and
broaden the target audience.


The takeover involves keeping the company’s 70 current employees in France, 54 of which are on the production site in the
Dardilly workshops.


Alain Schimel, his son Laurent and the family are delighted that the brand, founded in 1965 and labelled as a Living Heritage
Company since 2010, will pursue its legacy, and that the know-how cultivated in the Lyon workshops by several generations
of craftsmen and women will be preserved thanks to the significant investments that are set out in the new shareholders’
investment plan.


Giuseppe Di Nuccio, 52 years old, will lead the new company. Mr. Di Nuccio brings with him 25 years’ experience in directorship
roles at luxury brands such as Jil Sander, Burberry and Giorgio Armani.


Anthony de Rauville, CIO of Negma Group, comments: “ZILLI is a high-value company with considerable human capital.
ZILLI is a strategic, long-term acquisition for Negma and we are happy to provide our human and capital resources, which are
essential to develop the ZILLI brand and bring it to centre stage”.


Guglielmo Ruggeri, Directeur General of FAI, declares: “We are very proud to be given the responsibility for ZILLI house.
We will be bringing in a very professional team, which will work hand-in-hand with the teams in place to create the platform that
is needed for sustainable growth and the creation of value over the long term.”